All In Biotech

Drug Trial Radar · NCT07235020

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jan 23, 2024

Primary completion

Jan 30, 2025

Study completion Feb 21, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

  • INE963Drug

    Administered via oral INE963

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parasite clearance time (PCT)Time frame: up to Day 7

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Banfora, Burkina Faso

  • Novartis Investigative Site

    Azaguié, Côte d’Ivoire

  • Novartis Investigative Site

    Lambaréné, Gabon

  • Novartis Investigative Site

    Navrongo, Ghana

  • Novartis Investigative Site

    Kisumu, Kenya

  • Novartis Investigative Site

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.